Quote · The Peter Attia Drive
#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results
Where this was said
Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype
At 18:30 · chapter starts 17:00
Peter argues that the psychological dimension of genetic testing is one of its most underappreciated aspects. He recounts two contrasting patient stories: one who dissolved in relief upon learning they had not inherited a devastating familial mutation, and another who was consumed by unproductive fear for years after receiving an elevated-risk result [1] — Peter Attia "Genetic results can bring profound relief — patients who learn they didn't inherit a devastating familial mutation sometimes cry with joy. …" 19:15 . The key insight is that information is not automatically useful simply because it is true. A result that generates fear or confusion without changing screening, treatment, or planning has real costs — and those costs must be factored in before any test is ordered. Peter then distills the decision to test into four questions: What exactly are you trying to learn? Is genetics the best tool for this question, or would measuring the phenotype directly be more informative? If you get an answer, what will you do differently? And are you mentally prepared for whatever the result might be? These four questions, he argues, should be the starting framework for any conversation about genetic testing.
For most cardiovascular and metabolic risk factors, directly measuring cholesterol, blood pressure, or insulin resistance gives you a real-time, integrated readout that is more actionable than any genetic estimate. The genotype is source code; the phenotype is the running program.
Genetic results can bring profound relief — patients who learn they didn't inherit a devastating familial mutation sometimes cry with joy. But the same information can also consume patients in unproductive fear for years. The psychological cost of a frightening result must be part of the calculation before any test is ordered.
For someone with markedly elevated LDL and a suggestive family history, genetic confirmation of familial hypercholesterolemia can solidify the diagnosis, facilitate insurance coverage for medication, and trigger cascade screening of relatives who may be affected without knowing it.
SCARB1 mutations can make HDL cholesterol appear falsely elevated, giving patients a false sense of cardiovascular security. Peter Attia caught this diagnosis in a friend with an HDL of 100 and LDL of 80 whose calcium score revealed widespread atherosclerosis.
